Table 1.
Associations between ZNF331 methylation and clinical and molecular features
| Total | ZNF331 unmethylated | ZNF331 methylated | P value | |
|---|---|---|---|---|
| n | n (%) | n (%) | ||
| No. of patients | 423 | 122 (29) | 301 (71) | |
| Gender | 0.165 | |||
| Male | 213 | 68 (32) | 145 (68) | |
| Female | 210 | 54 (26) | 156 (74) | |
| Age | 0.074 | |||
| < 60 | 70 | 26 (37) | 44 (63) | |
| 60–74 | 178 | 55 (31) | 123 (69) | |
| ≥ 75 | 175 | 41 (23) | 134 (77) | |
| Stage | 0.683 | |||
| I | 79 | 20 (25) | 59 (75) | |
| II | 169 | 51 (30) | 118 (70) | |
| III | 118 | 32 (27) | 86 (73) | |
| IV | 56 | 19 (34) | 37 (66) | |
| Localization | < 0.001 | |||
| Right colon | 167 | 27 (16) | 140 (84) | |
| Left colon | 130 | 47 (36) | 83 (64) | |
| Rectum | 121 | 46 (38) | 75 (62) | |
| MSI status | < 0.001 | |||
| MSS | 325 | 111 (34) | 214 (66) | |
| MSI | 89 | 8 (9) | 81 (91) | |
| BRAF | < 0.001 | |||
| BRAF wt | 356 | 120 (34) | 236 (66) | |
| BRAF mut | 67 | 2 (3) | 65 (97) | |
| CIMP | < 0.001 | |||
| CIMP− | 355 | 121 (34%) | 234 (66) | |
| CIMP+ | 65 | 0 (0) | 65 (100) | |
| MLH1 methylation | < 0.001 | |||
| MLH1 unmeth | 360 | 117 (32.5) | 243 (67.5) | |
| MLH1 meth | 60 | 4 (7) | 56 (93) | |
| Series | 0.439 | |||
| Oslo 3 | 59 | 14 (24) | 45 (76) | |
| Oslo 2 | 364 | 108 (30) | 256 (70) |
Meth methylated, mut mutation, No. number, unmeth unmethylated, wt wild type